Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

BACKGROUND AND PURPOSE: The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 fractions combined with temozolomide (TMZ) or TMZ and bevacizumab (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohno, Makoto, Miyakita, Yasuji, Takahashi, Masamichi, Igaki, Hiroshi, Matsushita, Yuko, Ichimura, Koichi, Narita, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852964/
https://www.ncbi.nlm.nih.gov/pubmed/31718669
http://dx.doi.org/10.1186/s13014-019-1389-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852964/
https://www.ncbi.nlm.nih.gov/pubmed/31718669
http://dx.doi.org/10.1186/s13014-019-1389-7

Ejemplares similares